Navigation Links
GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
Date:12/3/2008

e condition that, at the expiration of the offer, there have been validly tendered and not withdrawn that number of shares which, together with the number of shares, if any, then beneficially owned by GSK and its wholly-owned subsidiaries, constitutes at least 90 percent of the total number of the then outstanding Genelabs shares on a fully diluted basis. The terms and conditions of the tender offer are set forth in the Offer to Purchase dated November 12, 2008.

Questions and requests for assistance may be directed to the Information Agent for the offer, MacKenzie Partners, Inc., at (212) 929-5500 or (800) 322-2885 (toll free).

About GlaxoSmithKline plc

GlaxoSmithKline plc -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information including a copy of this announcement and details of the company's updated product development pipeline, visit GSK at http://www.gsk.com.

Important information

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Genelabs. The solicitation and the tender offer to buy shares of Genelabs is only being made pursuant to the Offer to Purchase and related materials that GSK and Gemstone Acquisition Corporation filed with the Securities and Exchange Commission (SEC) on November 12, 2008 and as subsequently amended. Investors and security holders should read these materials carefully because they contain important information, including the terms and conditions of the tender offer. Investors and security holders may obtain free copies of the materials filed with the SEC by GSK and Genelabs relating to the tender offer through the web site maintained by the SEC at '/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
2. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
3. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
4. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
5. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
6. GlaxoSmithKline To Post Quarterly US Grants Report
7. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
8. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
9. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
10. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
11. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , 22. Juli 2014 Qforma, ein ... die Ernennung von Marcus Bergler zum General Manager ... hat die europäischen kommerziellen Aktivitäten von Qforma bereits ... sich Qforma anschloss, war er in Positionen als ... als Vertriebsteam-Leiter Deutschland bei IMS Health und als ...
(Date:7/22/2014)... Greenville, SC (PRWEB) July 22, 2014 ... chorus of those who have recognized that the greatest ... inefficient, and far too often needlessly deadly while trying ... the multitude of quasi-experts seeking to transform an enormous ... detail.” , Dr. Williams, in his continuing series of ...
(Date:7/21/2014)... the right amount of tension to a chain of ... to an insulator, according to Rice University scientists. , ... one-dimensional chain of carbon atoms -- by just 3 ... that engineers might find useful for mechanically activated nanoscale ... physicist Boris Yakobson and his colleagues appears in the ...
(Date:7/21/2014)... 2014  Mike Patterson, CEO of Graphene Frontiers, ... Series Seed B funding to finance production of ... life science, defense, intelligence, and environmental industries.  A ... round and was joined by R2M Investments.  Return ... , "This round of funding will ensure Graphene ...
Breaking Biology Technology:Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Carbyne morphs when stretched 2Carbyne morphs when stretched 3Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2
... and TOKYO, Aug. 15, 2011 A new post-hoc ... TRITON-TIMI 38 study – those identified as the "core ... (in combination with aspirin) was associated with a 26 ... of cardiovascular death, myocardial infarction or stroke, compared to ...
... team of researchers from the National Institute of ... the University of Maryland has made nano-sized sensors ... paints, cleaners, pesticides and other productsthat offer several ... room-temperature operation and the ability to detect one ...
... and portable detector that takes just fifteen minutes to ... being developed by US researchers. The technology amplifies any ... the presence of just 40 microscopic cells of the ... as anthrax, is a potentially lethal microbe that might ...
Cached Biology Technology:Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 3Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 6Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 7Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 8Nanowire-based sensors offer improved detection of volatile organic compounds 2Nano detector for deadly anthrax 2
(Date:7/22/2014)... as a world-famous vacation spot with natural tourism resources, a ... The Korea Institute of Geoscience and Mineral Resources (KIGAM) indicated ... volcanic eruption was evident 5,000 years ago. That is the ... spewed out of a volcano 5,000 years ago in the ... the whole peninsula. , The research team led by Dr. ...
(Date:7/22/2014)... prevent their daughters from breeding, and kill their grandchildren ... desert creatures which live in groups with a dominant ... alpha female can flourish when it maintains the sole right ... life, also found in many animals such as ants and ... Dominant meerkats control breeding within their group through violence, by ...
(Date:7/22/2014)... July 22, 2014, Cleveland: A type of immune ... diseases, such as Alzheimer,s disease and multiple sclerosis ... brain injury (TBI) and may slow the progression ... published today in the online journal Nature ... Bruce Trapp, PhD, Chair of the Department of ...
Breaking Biology News(10 mins):Jeju Island is a live volcano 2Cleveland Clinic researchers discover neuroprotective role of immune cell 2
... (HLB), meaning "yellow shoot disease" in Chinese and ... the most destructive disease threatening the citrus industry ... are desired to control it. A new study, ... contributing factor in symptom expression for citrus Huanglongbing ...
... The Alfred P. Sloan Foundation is pleased to announce ... as recipients of Sloan Research Fellowships for 2013. ... to early-career scientists and scholars whose achievements and potential ... scientific leaders. "The Sloan Research Fellows are the ...
... Research Centre at Saint Mary,s Hospital and The University ... causing an inherited form of tumour, known as spinal ... Meningiomas are the commonest form of tumour affecting the ... surgery and do not recur. Occasionally people can develop ...
Cached Biology News:Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 2Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 3Sloan Foundation announces 2013 Sloan Research Fellows 2Researchers in Manchester find genetic key to preventing spine tumors 2
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic acid stain has also found uses ... bandshift assays. A 500 µL unit size (S-7563) ...
... cross-linking techniques are defined by the author ... Wong. This valuable hardcover guide includes hundreds ... application references. More than 300 pages detail ... conjugate preparation from selection and design ...
... protein separation by two-dimensional electrophoresis (2D-PAGE), ... package from Bio-Rad and protein identification ... to meet customers requirements regarding experimental ... format of the results permanent contact ...
... reagents for immune complex disruption (ICD) of ... using a combination of low pH and ... transferred to microplate wells which are coated ... to HIV-1 p24. The immobilized monoclonal antibody ...
Biology Products: